The global injection pen market size was valued at USD 37,899.00 million in 2021 and is projected to reach USD 80,511.51 million by 2031, growing at a CAGR of 7.8% from 2022 to 2031.

Major factors driving the growth of the Injection Pen Market

One of the primary factors influencing the growth of the injection pen market share is the increase in the prevalence of chronic diseases like cancer and diabetes, as well as the population of older people.

The rise in the usage of sophisticated reusable injectable pens among diabetes patients is the main factor fueling the growth of the injection pen market. The increased usage of automated injection pens will also have an impact on market growth.

Injection Pen Market Trends

An increase in the prevalence of chronic illnesses like cancer and diabetes as well as an increase in the older population are expected to boost the pen market. The incidence of diabetes is a significant, virtually pandemic public health problem on a global scale. Globally, the prevalence of chronic, noncommunicable diseases is growing dramatically. 90–95 percent of Americans have type 2 diabetes, which is significantly influenced by obesity. Both the incidence of diabetes and the prevalence of obesity are increasing in the US.

The rise in the usage of technologically advanced reusable injectable pens among diabetes patients is the main factor driving the Injection Pen Market expansion. The smart Injection Pen is a reusable injector pen with intuitive smartphone software that may be useful for people with diabetes. This ingenious system keeps track of doses, computes them, and generates reports, alerts, and reminders—all very helpful things. They might be a reusable device that utilizes prefilled cartridges rather than vials or single-use pens, or they could be an attachment for your current insulin pen.

Healthcare workers are increasingly using automated injection pens because of how accurately, safely, and easily they can provide medication. The necessity for injectable pens is being witnessed not just in affluent nations but also in developing countries because of the huge increase in senior people, who are more prone to chronic illnesses like diabetes and cancer. These are the factors propelling the growth of the injection pen market.

The growing geriatric population throughout the world is expected to boost the injection pen industry over the predicted time period. People's overall immunity declines with age, which can result in a number of health issues, including chronic conditions like diabetes and cardiovascular disease.

Injection Pen Market Share Analysis

The disposable and reusable segments of the injection pen market are separated. The disposable injection pens segment held the largest share of the market in 2021 and is anticipated to maintain its dominance throughout the forecast period. This is due to the increased adoption of disposable injection pens around the world to reduce the risk of cross-contamination and needle stick injuries associated with reusable injection pens.

By therapy

Market segments for injectable pens include those for diabetes, growth hormones, osteoporosis, and other conditions. In 2021, the diabetes market category had the largest market share, and it is anticipated that it would maintain this position for the duration of the projection. Growth in the older population and the prevalence of diabetes account for this. By 2050, 26.7 million Americans over 65 are estimated to have been diagnosed with diabetes, up from the anticipated 10.9 million in 2020, according to Caspersen et al.

Hospitals & clinics and home-care settings make up two segments of the injection pen market. The home-care settings market saw the highest growth in 2021 and is anticipated to keep leading during the forecast period due to rising disposable income, rising consumer healthcare spending, and rising patient adoption of cutting-edge drug delivery devices.

In the analysis of the injection pen market, North America, Europe, Asia-Pacific, and LAMEA are all taken into account. Sales of injection pens were large in North America in 2021, and it is projected that this dominance will throughout the whole projection period. The United States has been the major contributor to the growth of the injectable pen market in North America because of the increasing prevalence of chronic diseases and the need for safe and effective medication delivery. It is also helpful that there are several prominent injectable pen market players in North America, including Sanofi, Eli Lilly, Novo Nordisk, and Becton Dickinson, who have made considerable R&D expenditures to develop cutting-edge technologies.

Market Competition Analysis

The report provides competitive analysis and profiles of the major players in the injection pen market, such as Eli Lily and Company, Novo Nordisk A/S, Sanofi, Biocon Limited, AstraZeneca, Pfizer Inc, Becton, Dickinson and Company, Ypsomed AG, Novartis AG and Merck KGaA.

Recent product upgrade/development in injection pen market

In February 2023, AstraZeneca and Amgen’s Tezspire (tezepelumab) pre-filled pen was approved in the U.S. by the U.S. Food and Drug Administration (FDA). Tezspire pre-filled pen is used for self-administration in patients aged 12 years and older with severe asthma. Thus, launch of the new injection pen device will help the company to gain a strong foothold in the injection pen industry.
In October 2020, Ypsomed AG developed the YpsoMate Zero the world’s first zero carbon emission prefilled autoinjector.

Recent collaborations in injection pen market

In March 2020, Ypsomed AG collaborated with Teva Pharmaceutical Industries Ltd. to launch Teva's drug product AJOVY in the pre-filled YpsoMate 2.25 autoinjector. This collaboration with Teva marks the first commercial market entry of Ypsomed’s YpsoMate 2.25 autoinjector.

Key Benefits for Stakeholder

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the injection pen market analysis from 2021 to 2031 to identify the prevailing injection pen market opportunity.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the injection pen market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global injection pen market trends, key players, market segments, application areas, and market growth strategies.

Injection Pen Market Scope

Report Metric	Details
Report Name	Injection Pen Market
Market Size By 2031	USD 80.5 billion
Growth Rate	CAGR of 7.8%
By Company	AstraZeneca, Ypsomed AG, Becton, Dickinson and Company, Pfizer Inc., Novartis AG, Sanofi, Eli Lilly and Company, Merck Group, Novo Nordisk A/S, Biocon
Segment by Therapy	Growth Hormone Osteoporosis Fertility Others Diabetes
Application	Home-care Settings Hospital and clinics
Forecasted years	2022-2031
Segment by Type	Disposable injection pen Reusable injection pen
Forecast units	USD Billion in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Frequently Asked Questions About This Report

1.How Big is the Injection Pen Market?

Ans. The global injection pen market size was valued at $ 37,899.00 million in 2021 and is projected to reach $80,511.51 million by 2031, growing at a CAGR of 7.8% from 2022 to 2031.

2. Which is the most lucrative segment By Therapy for Injection Pen Market Growth?

Ans. Diabetes segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period.

3. Which region holds the dominant position for Injection Pen Market?

Ans. North America accounted for a majority of the injection pen market share in 2021 and is anticipated to remain dominant during the forecast period.

4. Which is the most lucrative segment By type for Injection Pen Market Growth?

Ans. Disposable injection pen segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period.

5. Which is the most lucrative segment By end user for Injection Pen Market Growth?

Ans. Home-care settings segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period.

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of chronic disease.

3.4.1.2. Surge in awareness for self-injectables

3.4.1.3. Rise in technological advancement

3.4.2. Restraints

3.4.2.1. Preference for alternative drug delivery modes

3.4.2.2. Increase in the number of needlestick injury

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies.

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: INJECTION PEN MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Disposable injection pen

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Reusable injection pen

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: INJECTION PEN MARKET, BY THERAPY

5.1. Overview

5.1.1. Market size and forecast

5.2. Diabetes

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Growth Hormone

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Osteoporosis

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Fertility

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Others

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

CHAPTER 6: INJECTION PEN MARKET, BY END USERS

6.1. Overview

6.1.1. Market size and forecast

6.2. Home-care Settings

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Hospital and clinics

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

CHAPTER 7: INJECTION PEN MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Type

7.2.3. Market size and forecast, by Therapy

7.2.4. Market size and forecast, by End Users

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Type

7.2.5.1.3. Market size and forecast, by Therapy

7.2.5.1.4. Market size and forecast, by End Users

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Type

7.2.5.2.3. Market size and forecast, by Therapy

7.2.5.2.4. Market size and forecast, by End Users

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Type

7.2.5.3.3. Market size and forecast, by Therapy

7.2.5.3.4. Market size and forecast, by End Users

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Type

7.3.3. Market size and forecast, by Therapy

7.3.4. Market size and forecast, by End Users

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Type

7.3.5.1.3. Market size and forecast, by Therapy

7.3.5.1.4. Market size and forecast, by End Users

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Type

7.3.5.2.3. Market size and forecast, by Therapy

7.3.5.2.4. Market size and forecast, by End Users

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Type

7.3.5.3.3. Market size and forecast, by Therapy

7.3.5.3.4. Market size and forecast, by End Users

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Type

7.3.5.4.3. Market size and forecast, by Therapy

7.3.5.4.4. Market size and forecast, by End Users

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Type

7.3.5.5.3. Market size and forecast, by Therapy

7.3.5.5.4. Market size and forecast, by End Users

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Type

7.3.5.6.3. Market size and forecast, by Therapy

7.3.5.6.4. Market size and forecast, by End Users

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Type

7.4.3. Market size and forecast, by Therapy

7.4.4. Market size and forecast, by End Users

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Type

7.4.5.1.3. Market size and forecast, by Therapy

7.4.5.1.4. Market size and forecast, by End Users

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Type

7.4.5.2.3. Market size and forecast, by Therapy

7.4.5.2.4. Market size and forecast, by End Users

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Type

7.4.5.3.3. Market size and forecast, by Therapy

7.4.5.3.4. Market size and forecast, by End Users

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Type

7.4.5.4.3. Market size and forecast, by Therapy

7.4.5.4.4. Market size and forecast, by End Users

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Type

7.4.5.5.3. Market size and forecast, by Therapy

7.4.5.5.4. Market size and forecast, by End Users

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Type

7.4.5.6.3. Market size and forecast, by Therapy

7.4.5.6.4. Market size and forecast, by End Users

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Type

7.5.3. Market size and forecast, by Therapy

7.5.4. Market size and forecast, by End Users

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Type

7.5.5.1.3. Market size and forecast, by Therapy

7.5.5.1.4. Market size and forecast, by End Users

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Type

7.5.5.2.3. Market size and forecast, by Therapy

7.5.5.2.4. Market size and forecast, by End Users

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Type

7.5.5.3.3. Market size and forecast, by Therapy

7.5.5.3.4. Market size and forecast, by End Users

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Type

7.5.5.4.3. Market size and forecast, by Therapy

7.5.5.4.4. Market size and forecast, by End Users

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Eli Lilly and Company

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. AstraZeneca

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Ypsomed AG

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Becton, Dickinson and Company

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Merck Group

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Pfizer Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Novartis AG

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Sanofi

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Novo Nordisk A/S

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Biocon

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

FEATURED COMPANIES

Astrazeneca plc

Ypsomed

Becton

Dickinson and Company

Pfizer Inc

Novartis

Sanofi

Eli Lilly and Company

Merck Group

Novo Nordisk A S

Biocon Ltd.

LIST OF TABLES

TABLE 01. GLOBAL INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 02. INJECTION PEN MARKET FOR DISPOSABLE INJECTION PEN, BY REGION, 2021-2031 ($MILLION)
TABLE 03. INJECTION PEN MARKET FOR REUSABLE INJECTION PEN, BY REGION, 2021-2031 ($MILLION)
TABLE 04. GLOBAL INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 05. INJECTION PEN MARKET FOR DIABETES, BY REGION, 2021-2031 ($MILLION)
TABLE 06. INJECTION PEN MARKET FOR GROWTH HORMONE, BY REGION, 2021-2031 ($MILLION)
TABLE 07. INJECTION PEN MARKET FOR OSTEOPOROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 08. INJECTION PEN MARKET FOR FERTILITY, BY REGION, 2021-2031 ($MILLION)
TABLE 09. INJECTION PEN MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. GLOBAL INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 11. INJECTION PEN MARKET FOR HOME-CARE SETTINGS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. INJECTION PEN MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. INJECTION PEN MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. U.S. INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 19. U.S. INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 20. U.S. INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 21. CANADA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 22. CANADA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 23. CANADA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 24. MEXICO INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. MEXICO INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 26. MEXICO INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 27. EUROPE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 28. EUROPE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 29. EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 30. EUROPE INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. GERMANY INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. GERMANY INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 33. GERMANY INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 34. FRANCE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. FRANCE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 36. FRANCE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 37. UK INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 38. UK INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 39. UK INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 40. ITALY INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. ITALY INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 42. ITALY INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 43. SPAIN INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. SPAIN INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 45. SPAIN INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. JAPAN INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. JAPAN INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 55. JAPAN INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 56. CHINA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. CHINA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 58. CHINA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 59. AUSTRALIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. AUSTRALIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 61. AUSTRALIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 62. INDIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. INDIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 64. INDIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 67. SOUTH KOREA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 71. LAMEA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. LAMEA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 73. LAMEA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 74. LAMEA INJECTION PEN MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 75. BRAZIL INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 76. BRAZIL INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 77. BRAZIL INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 80. SAUDI ARABIA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 81. SOUTH AFRICA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. SOUTH AFRICA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 83. SOUTH AFRICA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA INJECTION PEN MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA INJECTION PEN MARKET, BY THERAPY, 2021-2031 ($MILLION)
TABLE 86. REST OF LAMEA INJECTION PEN MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 87. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 88. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 89. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 90. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 91. ASTRAZENECA: KEY EXECUTIVES
TABLE 92. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 93. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 94. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 95. ASTRAZENECA: KEY STRATERGIES
TABLE 96. YPSOMED AG: KEY EXECUTIVES
TABLE 97. YPSOMED AG: COMPANY SNAPSHOT
TABLE 98. YPSOMED AG: PRODUCT SEGMENTS
TABLE 99. YPSOMED AG: PRODUCT PORTFOLIO
TABLE 100. YPSOMED AG: KEY STRATERGIES
TABLE 101. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
TABLE 102. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 103. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
TABLE 104. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 105. MERCK GROUP: KEY EXECUTIVES
TABLE 106. MERCK GROUP: COMPANY SNAPSHOT
TABLE 107. MERCK GROUP: PRODUCT SEGMENTS
TABLE 108. MERCK GROUP: PRODUCT PORTFOLIO
TABLE 109. PFIZER INC.: KEY EXECUTIVES
TABLE 110. PFIZER INC.: COMPANY SNAPSHOT
TABLE 111. PFIZER INC.: PRODUCT SEGMENTS
TABLE 112. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 113. NOVARTIS AG: KEY EXECUTIVES
TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 117. SANOFI: KEY EXECUTIVES
TABLE 118. SANOFI: COMPANY SNAPSHOT
TABLE 119. SANOFI: PRODUCT SEGMENTS
TABLE 120. SANOFI: PRODUCT PORTFOLIO
TABLE 121. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 122. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 123. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 124. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 125. BIOCON: KEY EXECUTIVES
TABLE 126. BIOCON: COMPANY SNAPSHOT
TABLE 127. BIOCON: PRODUCT SEGMENTS
TABLE 128. BIOCON: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. INJECTION PEN MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF INJECTION PEN MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN INJECTION PEN MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALINJECTION PEN MARKET
FIGURE 10. INJECTION PEN MARKET, BY TYPE, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR DISPOSABLE INJECTION PEN, BY COUNTRY 2021-2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR REUSABLE INJECTION PEN, BY COUNTRY 2021-2031(%)
FIGURE 13. INJECTION PEN MARKET, BY THERAPY, 2021(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR DIABETES, BY COUNTRY 2021-2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR GROWTH HORMONE, BY COUNTRY 2021-2031(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR OSTEOPOROSIS, BY COUNTRY 2021-2031(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR FERTILITY, BY COUNTRY 2021-2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
FIGURE 19. INJECTION PEN MARKET, BY END USERS, 2021(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR HOME-CARE SETTINGS, BY COUNTRY 2021-2031(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF INJECTION PEN MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY 2021-2031(%)
FIGURE 22. INJECTION PEN MARKET BY REGION, 2021
FIGURE 23. U.S. INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 24. CANADA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 25. MEXICO INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 26. GERMANY INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 27. FRANCE INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 28. UK INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 29. ITALY INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 30. SPAIN INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 31. REST OF EUROPE INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 32. JAPAN INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 33. CHINA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 34. AUSTRALIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 35. INDIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 36. SOUTH KOREA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 38. BRAZIL INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 39. SAUDI ARABIA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 40. SOUTH AFRICA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 41. REST OF LAMEA INJECTION PEN MARKET, 2021-2031 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: INJECTION PEN MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2021
FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. YPSOMED AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. YPSOMED AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. YPSOMED AG: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 56. BECTON, DICKINSON AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. MERCK GROUP: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. MERCK GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. MERCK GROUP: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 65. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. SANOFI: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 70. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 71. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
FIGURE 72. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. BIOCON: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 75. BIOCON: REVENUE SHARE BY SEGMENT, 2021 (%)